[19] Patients with diabetes should coordinate with their diabetes care provider to adjust insulin or secretagogue doses during periods of poor oral intake to reduce hypoglycemia risk
however, this is not currently listed as a class contraindication in UK Summaries of Product Characteristics (SmPCs) for licensed GLP-1 receptor agonists, and patients should not assume a blanket prohibition applies
Although many medications dont require dose adjustments with GLP-1 therapy, individual circumstances often call for tailored approaches to address specific risks
This drives up your floating blood sugar while starving your cells and results in weight gain as your body is triggered to store fat, explains Midis Chief Clinical Officer, Mindy Goldman, MD , whos been a practicing OB/GYN at the University of California, San Francisco (UCSF) for almost three decades
Our comprehensive range of injectable compounds, including semaglutide, is designed to meet diverse patient needs effectively
Originally developed for patients with type II diabetes (with or without obesity), GLP-1R agonists are increasingly prescribed for obesity alone